165 related articles for article (PubMed ID: 26846183)
1. Temozolomide-induced biliary ductopenia: a case report.
Balakrishnan A; Ledford R; Jaglal M
J Med Case Rep; 2016 Feb; 10():33. PubMed ID: 26846183
[TBL] [Abstract][Full Text] [Related]
2. Severe cholestatic hepatitis due to temozolomide: an adverse drug effect to keep in mind. Case report and review of literature.
Grieco A; Tafuri MA; Biolato M; Diletto B; Di Napoli N; Balducci N; Vecchio FM; Miele L
Medicine (Baltimore); 2015 Mar; 94(12):e476. PubMed ID: 25816026
[TBL] [Abstract][Full Text] [Related]
3. Valproic acid related idiosyncratic drug induced hepatotoxicity in a glioblastoma patient treated with temozolomide.
Neyns B; Hoorens A; Stupp R
Acta Neurol Belg; 2008 Dec; 108(4):131-4. PubMed ID: 19239041
[TBL] [Abstract][Full Text] [Related]
4. Vanishing bile duct syndrome in the context of concurrent temozolomide for glioblastoma.
Mason M; Adeyi O; Fung S; Millar BA
BMJ Case Rep; 2014 Nov; 2014():. PubMed ID: 25432915
[TBL] [Abstract][Full Text] [Related]
5. [A case of allopurinol-induced granulomatous hepatitis with ductopenia and cholestasis].
Yoon JY; Min SY; Park JY; Hong SG; Park SJ; Paik SY; Park YM
Korean J Hepatol; 2008 Mar; 14(1):97-101. PubMed ID: 18367862
[TBL] [Abstract][Full Text] [Related]
6. Temozolomide induced liver injury.
Dixit S; Hingorani M; Afzal P; Campbell AP
Acta Neurol Belg; 2011 Sep; 111(3):249-51. PubMed ID: 22141295
[TBL] [Abstract][Full Text] [Related]
7. Severe sustained cholestatic hepatitis following temozolomide in a patient with glioblastoma multiforme: case study and review of data from the FDA adverse event reporting system.
Sarganas G; Orzechowski HD; Klimpel A; Thomae M; Kauffmann W; Herbst H; Bronder E; Garbe E
Neuro Oncol; 2012 May; 14(5):541-6. PubMed ID: 22394496
[TBL] [Abstract][Full Text] [Related]
8. Meropenem-induced vanishing bile duct syndrome.
Schumaker AL; Okulicz JF
Pharmacotherapy; 2010 Sep; 30(9):953. PubMed ID: 20812433
[TBL] [Abstract][Full Text] [Related]
9. Drug-induced cholestatic hepatitis: how late can it occur even after the cessation of the culpable drug?
Zamani N; Mohammad Alizadeh A
Neuro Oncol; 2012 Jul; 14(7):830. PubMed ID: 22544734
[No Abstract] [Full Text] [Related]
10. A rare case of aplastic anemia caused by temozolomide.
George BJ; Eichinger JB; Richard TJ
South Med J; 2009 Sep; 102(9):974-6. PubMed ID: 19668033
[TBL] [Abstract][Full Text] [Related]
11. A concurrent ultra-fractionated radiation therapy and temozolomide treatment: A promising therapy for newly diagnosed, inoperable glioblastoma.
Beauchesne P; Quillien V; Faure G; Bernier V; Noel G; Quetin P; Gorlia T; Carnin C; Pedeux R
Int J Cancer; 2016 Mar; 138(6):1538-44. PubMed ID: 26501997
[TBL] [Abstract][Full Text] [Related]
12. Temozolomide-induced liver damage. A case report.
Becker F; Hecht M; Schmidtner J; Semrau S; Fietkau R
Strahlenther Onkol; 2014 Apr; 190(4):408-10. PubMed ID: 24452817
[TBL] [Abstract][Full Text] [Related]
13. Acute temozolomide induced liver injury : Mixed type hepatocellular and cholestatic toxicity.
Aygun C; Altınok AY; Çakır A; Agan AF; Balaban Y
Acta Gastroenterol Belg; 2016; 79(4):487-489. PubMed ID: 28209108
[TBL] [Abstract][Full Text] [Related]
14. Reactivation of hepatitis B virus after glioblastoma treatment with temozolomide--case report.
Ohno M; Narita Y; Miyakita Y; Ueno H; Kayama T; Shibui S
Neurol Med Chir (Tokyo); 2011; 51(10):728-31. PubMed ID: 22027252
[TBL] [Abstract][Full Text] [Related]
15. Acute temozolomide induced liver injury: mixed type hepatocellular and cholestatic toxicity.
Aygun C; Altınok AY; Çakır A; Agan AF; Balaban Y
Acta Gastroenterol Belg; 2016; 79(2):363-365. PubMed ID: 27821033
[TBL] [Abstract][Full Text] [Related]
16. Vanishing bile duct syndrome related to DILI and Hodgkin lymphoma overlap: A rare and severe case.
Greca RD; Cunha-Silva M; Costa LBE; Costa JGF; Mazo DFC; Sevá-Pereira T; Nascimento MMC; Pereira IE; Oliveira FC; Faria GAS; Neto FLP; Almeida JRS
Ann Hepatol; 2020; 19(1):107-112. PubMed ID: 31537508
[TBL] [Abstract][Full Text] [Related]
17. Vanishing bile duct syndrome in Hodgkin's lymphoma: A case report and literature review.
Bakhit M; McCarty TR; Park S; Njei B; Cho M; Karagozian R; Liapakis A
World J Gastroenterol; 2017 Jan; 23(2):366-372. PubMed ID: 28127210
[TBL] [Abstract][Full Text] [Related]
18. Non-Hodgkin's lymphoma in a patient on treatment with temozolomide.
Otty Z; Sabesan S
Asia Pac J Clin Oncol; 2012 Dec; 8(4):e53-4. PubMed ID: 22897453
[TBL] [Abstract][Full Text] [Related]
19. Bile ductopenia following therapy with sulpiride.
Villari D; Rubino F; Corica F; Spinella S; Di Cesare E; Longo G; Raimondo G
Virchows Arch; 1995; 427(2):223-6. PubMed ID: 7582254
[TBL] [Abstract][Full Text] [Related]
20. Non-Hodgkin lymphoma following temozolomide.
Sharma A; Gupta D; Mohanti BK; Thulkar S; Dwary A; Goyal S; Muzumder S; Das P
Pediatr Blood Cancer; 2009 Oct; 53(4):661-2. PubMed ID: 19533661
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
